Wire flash
Sweden's Nanexa signs €1.165B deal with Novo Nordisk for long-acting obesity and diabetes injections
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 24, Swedish drug delivery platform company Nanexa announced a global exclusive license and collaboration agreement with Novo Nordisk. The deal leverages Nanexa's PharmaShell technology platform to develop long-acting injectable peptide drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications. The agreement covers up to five development projects with monthly and quarterly dosing frequency goals. Novo Nordisk will lead global development and commercialization. Nanexa is eligible for total payments of up to €1.165 billion, including a €615 million upfront payment and development and regulatory milestone payments, with the remainder being sales milestone payments. Additionally, Nanexa is entitled to low single-digit percentage royalties on global net sales of products developed under the agreement.
Source report
Stockholm, Sweden – September 24 – Nanexa, a Swedish drug delivery platform company, announced today that it has entered into a global exclusive licensing and collaboration agreement with Novo Nordisk. The partnership focuses on the use of Nanexa's PharmaShell® technology platform for peptide-based drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications.
Key Terms of the Agreement
- Scope: The agreement covers up to five development programs, with different dosing frequency regimens targeting monthly and quarterly administration.
- Development and Commercialization: Novo Nordisk will lead global development and commercialization efforts.
- Financial Considerations:
- Nanexa is eligible to receive total payments of up to €1.165 billion.
- This includes an upfront payment of €615 million, along with development and regulatory milestone payments.
- Additional milestone payments are tied to sales performance.
- Nanexa is also entitled to low single-digit percentage royalties on global net sales of products developed under the agreement.
Source
界面Neutral / independent
Part of this Story
Novo Nordisk signs €1.165 billion deal with Nanexa for long-acting obesity drug tech